104740-55-8

Basic information

• Product Name: 1-CBZ-4-(2-AMINOETHYL)PIPERAZINE
• Synonyms: 1-CBZ-4-(2-AMINOETHYL)PIPERAZINE;benzyl 4-(2-aminoethyl)piperazine-1-carboxylate;4-(2-Aminoethyl)piperazine-1-carboxylic acid benzyl ester;4-(2-Aminoethyl)-1-piperazinecarboxylic acid phenylmethyl ester;2-(N-Cbz-piperazin-1-yl)ethanamine
• CAS NO: 104740-55-8
• Molecular Formula: C₁₄H₂₁N₃O₂
• Molecular Weight: 263.33544
• Mol File: 104740-55-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 163-164℃ (isopropanol )
• Boiling Point: 403.7 °C at 760 mmHg
• Flash Point: 198 °C
• Appearance: /
• Density: 1.154±0.06 g/cm3 (20 ºC 760 Torr)
• PKA: 10.11±0.10(Predicted)
• CAS DataBase Reference: 1-CBZ-4-(2-AMINOETHYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-CBZ-4-(2-AMINOETHYL)PIPERAZINE(104740-55-8)
• EPA Substance Registry System: 1-CBZ-4-(2-AMINOETHYL)PIPERAZINE(104740-55-8)

Safety Data

• Hazardous Substances Data: 104740-55-8(Hazardous Substances Data)

Usage

General Description

1-Cbz-4-(2-Aminoethyl)piperazine is a chemical compound with the molecular formula C16H24N4O2. It is a derivative of piperazine, containing both a carbobenzyloxy (Cbz) protecting group and an aminoethyl group. 1-Cbz-4-(2-Aminoethyl)piperazine is commonly used in the synthesis of pharmaceuticals and as an intermediate in organic chemistry reactions. It is known for its potential as a building block in the production of various bioactive molecules and pharmaceutical drugs. Additionally, it has been studied for its role in drug delivery systems and as a potential therapeutic agent in the treatment of certain medical conditions.

Upstream product

• 81088-96-2 4-(2-chloroethyl)piperazine-1-carboxylic acid benzyl ester 
• 501-53-1 benzyl chloroformate 
• 100450-84-8 N-[phenylmethylidene]-2-piperazin-1-ylethanamine 
• 140-31-8 aminoethylpiperazine 
• 7646-93-7 potassium hydrogensulfate 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 

Downstream Products

• 636602-67-0 4-(2-ureidoethyl)piperazine-1-carboxylic acid benzyl ester 
• 500013-42-3 benzyl 4-(2-((tert-butoxycarbonyl)amino)ethyl)piperazine-1-carboxylate 
• 1710768-30-1 (R,E)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)piperidin-1-yl)-4-(4-(2-aminoethyl)piperazin-1-yl)but-2-en-1-one 
• 636602-68-1 1-[2-(1-benzyloxycarbonylpiperazin-4-yl)-ethyl]-6-methyl-1H,3H-pyrimidin-2,4-dione 
• 104740-41-2 4-<2-<<2-<2-(diethylamino)ethyl>-2,6-dihydro-6-oxoanthra<1,9-cd>pyrazol-5-yl>amino>ethyl>-1-piperazinecarboxylic acid phenylmethyl ester 
• 104740-56-9 4-{2-[2-(2-Hydroxy-ethyl)-6-oxo-2,6-dihydro-dibenzo[cd,g]indazol-5-ylamino]-ethyl}-piperazine-1-carboxylic acid benzyl ester 

Relevant articles and documents

NOVEL HETEROCYCLIC COMPOUNDS

The invention provides novel heterocyclic compounds having thegeneral formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R4, m, n, and p are as described herein. Formula (I). Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: A comparative study

Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) and has been approved for the treatment of haematological malignancies, such as chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenstr?m's macroglobulinemia. The covalent and irreversible nature of its molecular mode of action allows identification and monitoring of its target in an activity-based protein profiling (ABPP) setting. Fluorescent and biotinylated ibrutinib derivatives have appeared in the literature in recent years to monitor BTK in vitro and in situ. The work described here complements this existing methodology and pertains a comparative study on the efficacy of direct and two-step bioorthogonal ABPP of BTK.

Indol-2-one derivatives

-